AppTech Payments Unveils New Cloud-Based Product Platform

Fintech company AppTech Payments Corp (NASDAQ: APCX) launched its new product platform, Commerce, at Money20/20 USA, happening through October 26 at The Venetian in Las Vegas.
  • Fintech company AppTech Payments Corp (NASDAQ:APCX) launched its new product platform, Commerce, at Money20/20 USA, happening through October 26 at The Venetian in Las Vegas.
  • This first-to-market, cloud-based Commerce Experiences-as-a-Service (CXS) platform is backed by AppTech’s mobile commerce patents, core partner technology, and other internal intellectual property. 
  • CXS solutions incorporate PaaS, BaaS, Data, AI and ML, MarTech, and other features to create flexible, rich, personalized payment and banking experiences for end users.
  • According to Gartner, “By 2024, 15% of B2B organizations will use digital commerce platforms to support both customers and sales reps in all sales activities.” 
  • “‘One Platform. All Commerce.’ is our tagline for Commerce because it seamlessly delivers digital banking, text-to-pay, crypto payments, and merchant services altogether from a single, unified platform,” said AppTech’s Chief Operating Officer Chad Nelley.
  • AppTech collaborated with Chip Financial in October to support the company’s growing Fintech, digital banking, and payments ecosystem. 
  • The partnership enhanced Chip Financial’s suite of solutions focusing on a tailored customer approach to provide capabilities in Payments-as-a-Service (PaaS) and Banking-as-a-Service (BaaS).
  • Price Action: APCX shares traded lower by 13.55% at $0.7650 on the last check Monday.
Total
0
Shares
Related Posts
Read More

Biomea Fusion Announces Acceptance Of Three Abstracts For Its Novel Menin Inhibitor Highlighting Durable Glycemic Control In Diabetes Patients At The International Conference On Advanced Technologies & Treatments For Diabetes In 2024

New clinical data from all dosing cohorts (n=62) initiated to date from the escalation portion of COVALENT-111 and long-term (26 weeks) follow-up data of the 200 mg dosed cohorts will be featured during an oral Poster

BMEA